Antiretroviral News and Research

RSS

New study following 12,574 individuals over the course of three years of HAART

Although clinical progression to AIDS of patients infected with Human immunodeficiency virus (HIV) has declined since the introduction of Highly Active Antiretroviral Therapy (HAART), there is little data on the changes in incidence of AIDS-defining events during the first few years of therapy.

28 Feb 2005

Youth with HIV take more risks after new meds introduced

Teens with HIV are having more risky sex with more partners than their counterparts did in the years before powerful new medications for HIV were introduced in 1996, according to a new report in the American Journal of Health Behavior.

28 Feb 2005

New compounds for the treatment of HIV/AIDS

Scientists from Tibotec Pharmaceuticals Ltd. presented data on several new compounds for the treatment of HIV/AIDS at the 12th Conference on Retroviruses and Opportunistic Infections (CROI), held February 22-25 in Boston, MA, USA.

27 Feb 2005

Scientific rationale behind the use of antiretroviral therapy

Johns Hopkins researcher and infectious disease specialist Robert Siliciano, M.D., Ph.D., will provide an update on the scientific rationale behind the use of antiretroviral therapy, focusing on the mechanisms that allow life-long persistence of HIV even in patients on potent medication.

27 Feb 2005

Dual testing better for monitoring new cases of HIV

Johns Hopkins researchers will present results showing that tighter, dual testing standards work better for accurately distinguishing between new and old cases of HIV.

27 Feb 2005

Blips and AIDS therapy

Researchers at Johns Hopkins have concluded that sudden, temporary spikes in the amount of HIV in the body, commonly called blips, do not always mean the virus is developing resistance to AIDS drugs.

14 Feb 2005

New 3-DCR HIV strain does not respond to three classes of anti-retroviral medication

A highly resistant strain of rapidly progressive human immunodeficiency virus (HIV) has been diagnosed for the first time in a New York City resident who had not previously undergone antiviral drug treatment, according to the Department of Health and Mental Hygiene (DOHMH).

13 Feb 2005

Need for routine voluntary screening for HIV

A new cost-effectiveness analysis has led researchers from Duke University Medical Center and the Veterans Affairs (VA) Palo Alto Health Care System to recommend that routine voluntary screening for HIV

10 Feb 2005

Many alcohol dependent HIV patients need assistance adhering to medications

Supervised medication delivery or simplified dosing regimens may be needed to ensure that HIV-infected patients with a history of alcohol problems stick to their medication regimens, according to a new study by researchers at Boston University Medical Center.

8 Feb 2005

WHO announces $2 billion gap in financing for AIDS treatment

Today, at the Davos World Economic Forum in Switzerland, the World Health Organization (WHO) released a report showing a "rapid expansion" in the number of people living in poor countries gaining access to life-saving AIDS treatment.

26 Jan 2005

Tentative approval of co-packaged lamivudine/zidovudine fixed dose combination tablets and nevirapine tablets

The Food and Drug Administration (FDA) has announced the tentative approval of a co-packaged antiretroviral drug regimen manufactured by Aspen Pharmacare of South Africa for the treatment of HIV-1 infection in adults.

26 Jan 2005

New highly active agents against leishmaniasis

Parasitic diseases, especially leishmaniases and trypanosomiases, kill hundreds of thousands of people every year in the world, mainly in the countries of the South. The most severe form of leishmaniosis (kala-azar, the visceral form), induced by Leishmania donovani and L. infantum, affects about 500 000 people per year and proves fatal if no treatment is given.

25 Jan 2005

New federal guidelines for the use of antiretroviral drugs to prevent HIV infection

The Centers for Disease Control and Prevention (CDC) today announced new federal guidelines for the use of antiretroviral drugs to prevent HIV infection after exposure to HIV through sexual intercourse, sexual assault, injection drug use, or accidents.

20 Jan 2005

Potential cure for lymphoma in HIV patients

Stem cell transplants have become the standard of care for patients with relapsed lymphoma, but not for patients who suffer from both this disease and HIV.

7 Jan 2005

DermaVir, a novel treatment for HIV/AIDS, complements and improves present drug therapies

DermaVir, a novel treatment for HIV/AIDS, offers a new option which complements and improves present drug therapies. The vaccine, applied topically to the skin, has demonstrated efficacy in boosting immune responses and controlling virus replication in chronically infected monkeys.

6 Jan 2005

States to explore putting restrictions on AIDS drug Trizivir

AIDS Healthcare Foundation (AHF) has sent a letter dated October 20, 2004, to the heads of all state Medicaid programs asking them put in use treatment authorization request (TAR) procedures on GlaxoSmithKline's (GSK) fixed-dose combination AIDS drug, Trizivir, as a standalone regimen for treatment naïve patients.

6 Jan 2005

New technique could lead to more effective therapies for AIDS

When researchers came up with the powerful cocktail of anti-HIV drugs known as highly active antiretroviral therapy (HAART), they hoped they had found a way to finally rid the body of the virus. But they were wrong.

4 Jan 2005

The burgeoning Indian AIDS epidemic

India, home to one-sixth of the human race, has an AIDS epidemic. Five million Indians are living with HIV infection. The stakes are high; the government is racing against time.

21 Dec 2004

Imatinib mesylate (Gleevec) inhibits important pathways that spur cancer growth

A new clinical study has shown that imatinib mesylate (Gleevec) has activity in AIDS-related Kaposi's sarcoma (KS). Imatinib inhibits important pathways that spur cancer growth, resulting in the regression of KS tumors within 4 weeks in some patients. The study will be published November 30 in the Journal of Clinical Oncology (JCO).

30 Nov 2004

Viral Genetics announces effects of VGV-1 in antiretroviral non-responding HIV infections

Viral Genetics announced today that the results of a clinical trial of its investigational therapy for HIV infection, VGV-1, were recently published in a peer reviewed journal, HIV & AIDS Review.

29 Nov 2004